Novartis reports seven tumor cases in children treated with Zolgensma

Novartis has disclosed that seven children who received its gene therapy Zolgensma for spinal muscular atrophy were later found to have tumors.

The company said the cases were identified during post‑marketing surveillance and are being investigated to determine any causal link to the treatment.

The report underscores ongoing safety monitoring for high‑cost gene therapies and may prompt further regulatory review.